NASDAQ:CRVS - Corvus Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.75
  • Forecasted Upside: 149.08 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.71
▼ -0.07 (-2.52%)
1 month | 3 months | 12 months
Get New Corvus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRVS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRVS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$6.75
▲ +149.08% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Corvus Pharmaceuticals in the last 3 months. The average price target is $6.75, with a high forecast of $9.50 and a low forecast of $4.00. The average price target represents a 149.08% upside from the last price of $2.71.
Buy
The current consensus among 2 polled investment analysts is to buy stock in Corvus Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/1/2021HC WainwrightLower Price TargetBuy$12.00 ➝ $9.50Low
i
3/26/2021HC WainwrightLower Price TargetBuy$12.00 ➝ $9.50Low
i
2/10/2021MizuhoDowngradeBuy ➝ Neutral$7.00 ➝ $4.00Low
i
11/29/2020MizuhoReiterated RatingBuy$7.00Low
i
10/6/2020HC WainwrightBoost Price TargetBuy$10.00 ➝ $12.00Medium
i
7/30/2020MizuhoReiterated RatingBuy$7.00High
i
5/1/2020MizuhoReiterated RatingBuy$7.00High
i
3/13/2020WedbushLower Price TargetOutperform$11.00 ➝ $8.00Medium
i
3/10/2020HC WainwrightInitiated CoverageBuy$10.00High
i
Rating by S. Ramakanth at HC Wainwright
10/29/2019MizuhoReiterated RatingBuy$7.00Low
i
9/11/2019MizuhoInitiated CoverageBuy$7.00 ➝ $7.00High
i
5/29/2019Roth CapitalInitiated CoverageBuy ➝ Buy$5.00 ➝ $6.00Medium
i
Rating by T. Butler at Roth Capital
3/13/2019WedbushLower Price TargetOutperform$19.00 ➝ $11.00High
i
11/2/2018CowenReiterated RatingBuyLow
i
8/15/2018Credit Suisse GroupUpgradeNeutral ➝ Buy$11.00 ➝ $15.00Low
i
Rating by Michael Morabito at Credit Suisse Group AG
8/8/2018WedbushReiterated RatingOutperformHigh
i
Rating by R. Driscoll at Wedbush
6/5/2018Jefferies Financial GroupInitiated CoverageBuy$17.00High
i
3/2/2018CowenReiterated RatingBuyLow
i
8/23/2017Credit Suisse GroupUpgradeUnderperform ➝ Neutral$14.00High
i
8/8/2017WedbushReiterated RatingOutperform$26.00Medium
i
Rating by R. Driscoll at Wedbush
8/2/2017WedbushInitiated CoverageOutperform$26.00Medium
i
Rating by R. Driscoll at Wedbush
7/4/2017Credit Suisse GroupLower Price TargetOutperform$26.00 ➝ $17.00Medium
i
7/4/2017CowenReiterated RatingOutperformMedium
i
Rating by Boris Peaker at Cowen Inc
6/6/2017CowenReiterated RatingBuyLow
i
Rating by Boris Peaker at Cowen Inc
5/2/2017CowenReiterated RatingBuyHigh
i
5/1/2017Credit Suisse GroupDowngradeNeutral ➝ Underperform$10.00High
i
4/6/2017Credit Suisse GroupLower Price TargetOutperform$26.00 ➝ $17.00Medium
i
4/6/2017CowenReiterated RatingOutperformMedium
i
4/5/2017Cantor FitzgeraldReiterated RatingBuy$25.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
3/12/2017Cantor FitzgeraldReiterated RatingOverweight$23.00 ➝ $25.00High
i
9/27/2016Credit Suisse GroupReiterated RatingBuy$25.00N/A
i
8/6/2016Cantor FitzgeraldSet Price TargetBuy$23.00N/A
i
Rating by mara goldstein at Cantor Fitzgerald
6/2/2016BTIG ResearchInitiated CoverageBuyN/A
i
Rating by Dane Leone at BTIG Research
4/19/2016BTIG ResearchInitiated CoverageBuy$22.00N/A
i
4/18/2016Cantor FitzgeraldInitiated CoverageBuy$23.00N/A
i
Rating by M. Goldstein at Cantor Fitzgerald
4/18/2016CowenInitiated CoverageOutperformN/A
i
4/18/2016GuggenheimInitiated CoverageBuy$24.00N/A
i
4/18/2016Credit Suisse GroupInitiated CoverageOutperform$25.00N/A
i
(Data available from 4/18/2016 forward)
Corvus Pharmaceuticals logo
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.
Read More

Today's Range

Now: $2.71
$2.66
$2.77

50 Day Range

MA: $3.09
$2.73
$3.58

52 Week Range

Now: $2.71
$2.12
$6.88

Volume

239,491 shs

Average Volume

845,024 shs

Market Capitalization

$103.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Corvus Pharmaceuticals?

The following Wall Street analysts have issued reports on Corvus Pharmaceuticals in the last twelve months: HC Wainwright, Mizuho, and Zacks Investment Research.
View the latest analyst ratings for CRVS.

What is the current price target for Corvus Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Corvus Pharmaceuticals in the last year. Their average twelve-month price target is $6.75, suggesting a possible upside of 149.1%. HC Wainwright has the highest price target set, predicting CRVS will reach $9.50 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $4.00 for Corvus Pharmaceuticals in the next year.
View the latest price targets for CRVS.

What is the current consensus analyst rating for Corvus Pharmaceuticals?

Corvus Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRVS will outperform the market and that investors should add to their positions of Corvus Pharmaceuticals.
View the latest ratings for CRVS.

What other companies compete with Corvus Pharmaceuticals?

How do I contact Corvus Pharmaceuticals' investor relations team?

Corvus Pharmaceuticals' physical mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company's listed phone number is 650-900-4520 and its investor relations email address is [email protected] The official website for Corvus Pharmaceuticals is www.corvuspharma.com.